Volume 26, Issue 3 (Iranian South Medical Journal 2024)
Iran South Med J 2024, 26(3): 203-211 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi F. Primary Aldosteronism During Pregnancy: A Case Report. Iran South Med J 2024; 26 (3) :203-211
URL: http://ismj.bpums.ac.ir/article-1-1856-en.html
URL: http://ismj.bpums.ac.ir/article-1-1856-en.html
Department of Internal Medicine, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran , karimif2002@yahoo.com
Abstract: (1114 Views)
Primary aldosteronism (PA) is the most common cause of secondary hypertension, but its incidence during pregnancy is rare and less than 80 cases in pregnancy have been reported in literature to date. Here, we present a pregnant woman who delivered her first child in the presence of PA four years before, but in her second pregnancy, she developed severe hypertension associated with hypokalemia, and was admitted with preeclampsia. She lost her infant and received a diagnosis of PA due to an adrenal adenoma. After adrenalectomy, her blood pressure was normalized.
Type of Study: Case Report |
Subject:
Endocrine System
Received: 2023/10/4 | Accepted: 2023/12/24 | Published: 2024/02/26
Received: 2023/10/4 | Accepted: 2023/12/24 | Published: 2024/02/26
References
1. Litynski M. Hypertension caused by tumors of the adrenal cortex. Pol Tyg Lek (Wars) 1953; 8(6): 204-8. [PubMed]
2. Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol 2015; 172(1): R23-30. [DOI]
3. Zelinka T, Petrak O, Rosa J, et al. Primary aldosteronism and pregnancy. Kidney Blood Press Res 2020; 45(2): 275-85. [DOI]
4. Vidyasagar S, Kumar S, Morton A. Screening for primary aldosteronism in pregnancy. Pregnancy Hypertens 2021; 25: 171-4. [DOI]
5. Agrawal A, Wenger NK. Hypertension during pregnancy. Curr Hypertens Rep 2020; 22(9): 64. [DOI]
6. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34): 3165-3241. [DOI]
7. Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: A nationwide sample of delivery admissions. Am J Obstet Gynecol 2012; 206(2): 134.e1-8. [DOI]
8. Landau E, Amar L. Primary aldosteronism and pregnancy. Ann Endocrinol (Paris) 2016; 77(2): 148-60. [DOI]
9. Monticone S, Auchus RJ, Rainey WE. Adrenal disorders in pregnancy. Nat Rev Endocrinol 2012; 8(11): 668-78. [DOI]
10. Ronconi V, Turchi F, Zennaro MC, et al. Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronism. Clin Endocrinol (Oxf) 2011; 74(2): 278-9. [DOI]
11. Biglieri EG, Slaton PE Jr. Pregnancy and primary aldosteronism. J Clin Endocrinol Metab 1967; 27(11): 1628-32. [DOI]
12. Aoi W, Doi Y, Tasaki S, et al. Primary aldosteronism aggravated during peripartum period. Jpn Heart J 1978; 19(6): 946-53. [DOI]
13. Murakami T, Watanabe Ogura E, Tanaka Y, et al. High blood pressure lowered by pregnancy. Lancet 2000; 356(9246): 1980. [DOI]
14. Ananth CV, Duzyj CM, Yadava S, et al. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010. Hypertension 2019; 74(5): 1089-95. [DOI]
15. Quartermaine G, Lambert K, Rees K, et al. Hormone-secreting adrenal tumors cause severe hypertension and high rates of poor pregnancy outcome: A UK Obstetric Surveillance System study with case control comparisons. BJOG 2018; 125(6): 719-27. [DOI]
16. Nanba K, Omata K, Else T, et al. Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. J Clin Endocrinol Metab 2018; 103(10): 3869-76. [DOI]
17. Dutta RK, Söderkvist P, Gimm O. Genetics of primary hyperaldosteronism. Endocr Relat Cancer 2016; 23(10): R437-54. [DOI]
18. Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 2008; 29(9): 763-71. [DOI]
19. Forestiero V, Sconfienza E, Mulatero P, et al. Primary aldosteronism in pregnancy. Rev Endocr Metab Disord 2023; 24(1): 39-48. [DOI]
20. Wilson M, Morganti AA, Zervoudakis I, et al. Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy. Am J Med 1980; 68(1): 97-104. [DOI]
21. Morton A. Primary aldosteronism and pregnancy. Pregnancy Hypertens 2015; 5(4): 259-62. [DOI]
22. Eschler DC, Kogekar N, Pessah-Pollack R. Management of adrenal tumors in pregnancy. Endocrinol Metab Clin North Am 2015; 44(2): 381-97. [DOI]
23. Mahdavi M, Hoseinnezhad M, Vahabbi Moghaddam M. Radiation distribution in head and thorax computerized tomography. Iran South Med J 2014; 17(2): 201-206. [Article]
24. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014; 129(11): 1254-61. [DOI]
25. Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat fetuses following spironolactone treatment. Acta Endocrinol (Copenh) 1980; 95(4): 540-5. [DOI]
26. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31(4): 153-8. [DOI]
27. Cabassi A, Rocco R, Berretta R, et al. Eplerenone use in primary aldosteronism during pregnancy. Hypertension 2012; 59(2): e18-9. [DOI]
28. Gunganah K, Carpenter R, Drake WM. Eplerenone use in primary aldosteronism during pregnancy. Clin Case Rep 2016; 4(1): 81-2. [DOI]
29. Gehlert J, Morton A. Eplerenone as a treatment for resistant hypertension in pregnancy. Obstet Med 2021; 14(1): 35-8. [DOI]
30. Al-Ali NA, El-Sandabesee D, Steel SA, et al. Conn’s syndrome in pregnancy successfully treated with amiloride. J Obstet Gynaecol 2007; 27(7): 730-1. [DOI]
31. Ghela A, Kashif M, Akhtar S, et al. A challenging case of primary aldosteronism presenting in pregnancy. Endocr Abstr 2017; 50. [DOI]
32. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101(5): 1889-916. [DOI]
33. Mulatero P, Sechi LA, Williams TA, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hyperten 2020; 38(10): 1929-36. [DOI]
34. Shekhar S, Haykal R, Kamilaris C, et al. Curative resection of an aldosteronoma causing primary aldosteronism in the second trimester of pregnancy. Endocrinol Diabetes Metab Case Rep 2020; 2020: 200043. [DOI]
35. Shalhav AL, Landman J, Afane J, et al. Laparoscopic adrenalectomy for primary hyperaldosteronism during pregnancy. J Laparoendosc Adv Surg Tech A 2000; 10(3): 169-71. [DOI]
36. Shigematsu K, Nishida N, Sakai H, et al. Primary aldosteronism with aldosterone-producing adenoma consisting of pure zona glomerulosatype cells in a pregnant woman. Endocr Pathol 2009; 20(1): 66-72. [DOI]
37. Shiraishi K, Kikuta K, Nitta Y, et al. Laparoscopic adrenalectomy due to primary aldosteronism during pregnancy. Hinyokika Kiyo 2014; 60(8): 381-5. [PubMed]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
